Expression of metabolism-related proteins in lacrimal gland adenoid cystic carcinoma

American Journal of Clinical Pathology

Volumn 143, Issue 4, 2015, Pages 584-592

  Koo, Ja Seung ^a   Yoon, Jin Sook ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Adenoid cystic carcinoma; Lacrimal gland; Metabolism related protein; Protein expression; Salivary gland

Indexed keywords

AMINO ACID TRANSPORTER; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; GLUTAMATE DEHYDROGENASE; GLUTAMINASE; GLYCINE HYDROXYMETHYLTRANSFERASE; HEXOKINASE; HEXOKINASE 2; METABOLISM RELATED PROTEIN; MONOCARBOXYLATE TRANSPORTER 4; PHOSPHOSERINE PHOSPHATASE; PROTEIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE A; UNCLASSIFIED DRUG; GLS1 PROTEIN, HUMAN; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SHMT1 PROTEIN, HUMAN; SLC16A4 PROTEIN, HUMAN; SLC1A5 PROTEIN, HUMAN; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LACRIMAL GLAND; LACRIMAL GLAND ADENOID CYSTIC CARCINOMA; LACRIMAL GLAND TUMOR; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRION; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; SALIVARY GLAND; EYE TUMOR; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LACRIMAL APPARATUS; LACRIMAL GLAND DISEASE; PATHOLOGY; PROGNOSIS; SALIVARY GLAND TUMOR; YOUNG ADULT;

ADULT; AGED; AMINO ACID TRANSPORT SYSTEM ASC; CARCINOMA, ADENOID CYSTIC; DISEASE-FREE SURVIVAL; EYE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINASE; GLYCINE HYDROXYMETHYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; LACRIMAL APPARATUS; LACRIMAL APPARATUS DISEASES; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84930360450     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPXAYH10WENLTC     Document Type: Article

References (35)

1. Esmaeli B, Ahmadi MA, Youssef A, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004;20:22-26.
2. Henderson JW Adenoid cystic carcinoma of the lacrimal gland, is there a cure? Trans Am Ophthalmol Soc. 1987;85:312-319.
3. Florentine BD, Fink T, Avidan S, et al. Extra-salivary gland presentations of adenoid cystic carcinoma: a report of three cases. Diagn Cytopathol. 2006;34:491-494.
4. Matsuba HM, Simpson JR, Mauney M, et al. Adenoid cystic salivary gland carcinoma: a clinicopathologic correlation. Head Neck Surg. 1986;8:200-204.
5. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149-158.
6. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992;164:623-628.
7. Prokopakis EP, Snyderman CH, Hanna EY, et al. Risk factors for local recurrence of adenoid cystic carcinoma: the role of postoperative radiation therapy. Am J Otolaryngol. 1999;20:281-286.
8. Li N, Xu L, Zhao H, et al. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer. 2012;118:3945-3953.
9. Polito E, Leccisotti A. Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy. Ann Ophthalmol. 1993;25:422-426.
10. Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32:619-626.
11. Tse DT, Kossler AL, Feuer WJ, et al. Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013;120:1313-1323.
12. Bradley EA, Bradley DJ. Adenoid cystic carcinoma of the lacrimal gland: rare ⋯ lethal ⋯ cured? Ophthalmology. 2013;120:1311-1312.
13. Gensheimer MF, Rainey D, Douglas JG, et al. Neutron radiotherapy for adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2013;29:256-260.
14. Dang CV, Hamaker M, Sun P, et al. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl). 2011;89:205-212.
15. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
16. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35:427-433.
17. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, et al. Energy metabolism in tumor cells. FEBS J. 2007;274:1393-1418.
18. Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984;54:1062-1069.
19. Won KY, Kim GY, Kim YW, et al. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol. 2010;41:107-112.
20. van den Heuvel AP, Jing J, Wooster RF, et al. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012;13:1185-1194.
21. von Holstein SL, Fehr A, Persson M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120:2130-2138.
22. Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010;16:4722-4731.
23. Gomez-Maldonado J, Avila C, Torre F, et al. Functional interactions between a glutamine synthetase promoter and MYB proteins. Plant J. 2004;39:513-526.
24. Bonfitto VL, Demasi AP, Costa AF, et al. High-grade transformation of adenoid cystic carcinomas: a study of the expression of GLUT1 glucose transporter and of mitochondrial antigen. J Clin Pathol. 2010;63:615-619.
25. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3:187-197.
26. Fisel P, Kruck S, Winter S, et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. Clin Cancer Res. 2013;19:5170-5181.
27. Gotanda Y, Akagi Y, Kawahara A, et al. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. Anticancer Res. 2013;33:2941-2947.
28. Nakayama Y, Torigoe T, Inoue Y, et al. Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med. 2012;3:25-30.
29. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012;11:1108-1117.
30. Meijer TW, Schuurbiers OC, Kaanders JH, et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer. 2012;76:316-323.
31. Kuo CH, Miyazaki D, Nawata N, et al. Prognosis-determinant candidate genes identified by whole genome scanning in eyes with pterygia. Invest Ophthalmol Vis Sci. 2007;48:3566-3575.
32. Budai B, Komlosi V, Adleff V, et al. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with firstline FOLFIRI+bevacizumab. Pharmacogenet Genomics. 2012;22:69-72.
33. Morris DI, Robbins JD, Ruoho AE, et al. Forskolin photoaffinity labels with specificity for adenylyl cyclase and the glucose transporter. J Biol Chem. 1991;266:13377-13384.
34. Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476:346-350.
35. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69:7986-7993.